Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOPHYLATE vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of bronchial asthma,Chronic bronchitis,Emphysema,Acute asthmatic exacerbations (off-label)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2 and CYP3A4 isoenzymes.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 40-60% bound, primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
Vd is approximately 0.3-0.7 L/kg, indicating distribution into total body water. Higher Vd in hyperthyroid states, lower in obesity.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 80-100% for immediate-release; 90-100% for extended-release. Rectal: 80-90%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 30-50 m L/min: 50% of normal dose; GFR <30 m L/min: 25% of normal dose or extend interval to 12-24 hours.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated or 25% of normal dose with monitoring.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
10-15 mg/kg/dose orally every 6-8 hours; maximum 60 mg/kg/day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at 300 mg every 8 hours; titrate cautiously due to increased risk of accumulation and adverse effects.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None.
No FDA black box warning exists for this drug.
Narrow therapeutic index; monitor serum levels. Dosage should be individualized. Avoid excessive caffeine intake.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to xanthine derivatives, active peptic ulcer disease, and seizure disorders.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) and charcoal-grilled foods, which can reduce theophylline absorption. High-fat meals may increase absorption; take consistently with meals.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal nephrotoxicity. Late third trimester: Risk of premature closure of ductus arteriosus and persistent pulmonary hypertension of the newborn.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Contraindicated during breastfeeding due to high M/P ratio of 3.5, leading to significant infant exposure with potential for adverse effects including renal impairment and gastrointestinal bleeding.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. However, avoid use after 28 weeks gestation due to fetal renal effects.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
SYNOPHYLATE (theophylline) has a narrow therapeutic index; serum levels should be monitored to maintain 5-15 mcg/m L. Use with caution in patients with heart failure, liver disease, or COPD, as clearance is reduced. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and carbamazepine decrease levels. Avoid in seizure disorders.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without medical advice, as it affects drug levels.,Inform all healthcare providers you are taking this medication, especially if starting new drugs.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOPHYLATE vs AEROLATE SR, answered by our medical review team.
SYNOPHYLATE is a Bronchodilator that works by SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOPHYLATE and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOPHYLATE is: 400-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOPHYLATE and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOPHYLATE is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal n. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.